FDA Sent a Compounding Pharmacy a Warning Letter. Here's What It Says.
Author
Date Published
- Twitter
- Facebook
- LinkedIn
- Instagram
- Copy Link
On September 18, 2026 the FDA sent a warning letter to Empower Pharmacy in Houston, following an inspection the previous November (FDA). It makes five separate allegations. Let’s break down what the letter said, what it means in the industry, and what to draw from this new information.
Who This Helps
This is for you if you use a compounded GLP-1 and want to know how seriously to take it rather than a headline about it. For the wider legal picture, our piece on where compounded GLP-1s stand now covers the general industry state.
What a warning letter is
The name oversells it in one direction and undersells it in another. FDA describes a warning letter as a notification issued when it identifies what it believes are significant violations. The letter "provides an opportunity for the company or individual to address FDA's concerns and requests a response with a certain timeframe" (FDA).
So it states FDA's position and opens a process. The firm has 15 working days from September 18 to respond, and can argue that its products don't violate the law. FDA says these exchanges "may change the regulatory status of the issues discussed in the letter." As of September 29 that window is still open, but any response the company sends would be direct to the FDA (not publicly).
The industry is panicking over the FDA’s claims that Empower’s compounding of GLP-1s does not meet the customization exemptions, which would put compounded GLP-1s access at risk. The FDA also writes that investigators "noted serious deficiencies in your practices for producing drug products, which put patients at risk," and closes by saying failure to adequately address the violations "may result in legal action without further notice, including, without limitation, seizure and injunction."
The customization question four of the five allegations depend on
Section 503A of federal law exempts pharmacy compounding from FDA approval, from labeling with adequate directions for use, and from manufacturing-practice regulations, provided certain conditions are met. One condition is not compounding copies of commercially available drugs regularly or in inordinate amounts. The exception is a change made for an identified individual patient producing a significant difference for them, as determined by the prescriber.
FDA says that condition wasn't met. It lists products "including" tirzepatide with niacinamide at two different volumes and concentrations, and semaglutide with cyanocobalamin, which "appear to be essentially copies" of approved products. Evidence it says it collected "includes" orders lacking any prescriber determination at all, determinations that "appear to be repeated verbatim across many records, suggesting that they may be pre-generated for selection by the prescriber, rather than written by the prescriber for an identified individual patient," and production volume. FDA adds that "[t]he volume of products you are producing suggests that differences between products you are compounding and the FDA-approved products are pretextual."
FDA's conclusion from that is not hedged: the products "do not meet the conditions of section 503A and are not eligible for the exemptions in that section." Everything downstream follows. Without the exemption the products are unapproved new drugs, they're misbranded because adequate directions for use can't be written for a layperson, and they become subject to manufacturing-practice regulations they weren't previously held to. FDA charges all three.
The order counts are redacted in the public letter, so nobody outside can judge the scale. FDA also notes it previously exercised enforcement discretion here, which ended for compounded tirzepatide on March 5, 2025 and for semaglutide on April 24, 2025.
Find a provider in your state
Answer a few questions and see live pricing from the providers that ship where you live.
The one allegation that stands alone
FDA is explicit that the insanitary conditions provision doesn't depend on any of that: it "applies regardless of whether drug products you compound meet the conditions of section 503A." So however the copies question resolves, this one remains.
Investigators found products "intended or expected to be sterile" were prepared, packed or held under insanitary conditions "whereby they may have become contaminated with filth or rendered injurious to health." Two specifics:
- Smoke studies. FDA said the firm "failed to perform adequate smoke studies under dynamic conditions to demonstrate unidirectional airflow," so products "are produced in an environment that may not provide adequate protection against the risk of contamination."
- Media fills. These "were not performed under the most challenging or stressful conditions," leaving "a lack of assurance that your firm can aseptically produce drug products within your facility."
Separately, FDA lists five manufacturing-practice violations covering equipment maintenance, contamination procedures, the quality control unit, environmental monitoring and process controls. Those are charged against the products FDA says lost their exemption, so unlike the insanitary conditions finding, they do depend on the 503A question.
What FDA said about the fixes
The pharmacy responded three times, in December 2025, March 2026 and April 2026. FDA reviewed those responses and its answer splits three ways.
Some corrective actions on the insanitary conditions "appear adequate." A smoke study carried out March 30 to April 3, 2026 is one FDA says it "cannot fully evaluate" because the firm didn't include enough supporting documentation, noting the firm's own description that it "remains in controlled post-execution review." The media fill response "appear[s] deficient." This means the pharmacy did complete the smoke studies, they just didn't document the results well enough for the FDA.
On that last one, a January 2026 summary reported no contamination in any vial. FDA's review of the underlying records "revealed gaps and discrepancies": the summary didn't appear to match the vial count in the records, some entries were labeled "N/A" which is "not defined or explained in the records," and some results had been transcribed onto a different form revision. FDA states the firm's reason for that last one, that the originals were documented on the wrong form, and allows that it may have been done "for legitimate administrative reasons." Its concern is the absence of an audit trail: without one showing why results were rewritten and who authorized it, "this practice raises concerns about whether the data accurately reflects what actually occurred during the media fill."
A footnote adds that FDA is not addressing in this letter whether the proposed corrections would resolve the manufacturing-practice violations.
What to pay attention to
- The sterility findings. Not because any specific vial is implicated, but because this is the allegation that doesn't depend on how the legal question resolves, and FDA says the assurance wasn't there.
- Whether your medication could be among the ones listed. FDA's list is illustrative rather than exhaustive, so just because your medication is not specifically listed (and you got it from Empower) does not mean it might not be impacted.
- Whether a close-out letter follows. FDA issues one only after verifying corrections have actually been made, usually by follow-up inspection, and never "based on representations that some action will or has been taken" (FDA).
- FDA's standing advice on compounded GLP-1s: discard a multi-dose vial 28 days after first use, refuse anything that arrives warm, and don't buy products labeled for research purposes (FDA).
What you can set aside
- Claims that FDA banned or shut something down. It did neither. As of September 29, FDA's recall page lists no recall connected to this letter, though FDA notes that page doesn't carry every recall.
- Any order count attributed to this letter. The quantities are redacted, so a figure sourced to this document didn't come from it.
- The line about third-party platforms. FDA raised pre-selected menu options as a general example, introduced with "for example," of what would undermine an individual prescriber's judgment. It didn't find that this firm used one.
- Reading the letter as the full picture either way. FDA says the cited violations are "not intended to be an all-inclusive statement of violations at your facility," which means there may be more, and separately the firm can dispute all of them.
Final Takeaway
Four of the five allegations rise or fall with one legal question about whether an exemption applied. The insanitary conditions allegation doesn't, and FDA says so in terms. If you're on a compounded product, this letter doesn't tell you anything about your own vial, and the durable questions are the same ones as before it: which pharmacy fills your prescription, what its state license and inspection record look like (state boards directory), and why a compounded version is the right choice for you specifically.
If you enjoy posts like these, you can subscribe to receive newsletter updates.
Frequently Asked Questions
Has anything been recalled?
As of September 29, FDA's recall page lists no recall connected to this letter. A warning letter is not a recall, and FDA notes that not every recall appears on that page.
Does this mean my compounded medication is contaminated?
The letter doesn't say that. It describes conditions where products "may have become contaminated," which is a finding about process and risk rather than a test result on any particular vial.
Does this letter make compounded semaglutide or tirzepatide illegal?
It applies section 503A to one firm's records and reaches conclusions about that firm's products. It doesn't rule on anyone else's. The separate question of what compounding is permitted generally turned on the shortage listings, which ended in 2025, and we cover that elsewhere.
What happens next?
The firm has 15 working days from September 18 to respond and can dispute the findings. FDA may later issue a close-out letter if it verifies corrections, or pursue legal action, which it says could include seizure and injunction among other things.
Find a provider in your state
Answer a few questions and see live pricing from the providers that ship where you live.
Keep Reading
The FDA approved Foundayo (orforglipron) on April 1, 2026. Here is what the new once-daily GLP-1 pill actually changes for patients.
An FDA panel backed 6 of 7 peptides for the compounding list. See the votes, what each was proposed to treat, and what has to happen next.
Retatrutide is not FDA approved, but some clinics sell it anyway. See what the science shows and why approval status matters for you.
Categories
Written by
Lauren PescarusLauren Pescarus is a team member with GLP Winner where she works on marketing, content creation, and operations. She has over 10 years experience in the content creation space, including in the GLP-1 space where she works to stay on top of access news, research updates, and lifestyle tips guided by science.